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Abstract 
Introduction: Glucocorticoids are steroid 
hormones induced by stress that are necessary 
for proper glucose homeostasis and tissue 
development. Glucocorticoids also have potent 
immunosuppressant properties and are 
commonly used to treat a variety of 
inflammatory conditions such as asthma, cancer 
and autoimmune disease in children and adults. 
Chronic elevations due to excess stress or 
chronic glucocorticoid treatment can lead to metabolic disease.  Though glucocorticoid-induced 
metabolic disturbances such as insulin resistance, non-alcoholic fatty liver disease (NAFLD) and 
muscle wasting are well known, the impact of pre-existing obesity on metabolic syndrome and 
the specific transcriptional changes leading to these outcomes remain undefined.  Additionally, 
the effects of childhood glucocorticoid exposure on adult metabolic health is largely unknown. 
The aim of this dissertation is to identify the underlying physiological and mechanistic processes 
that lead to poor metabolic health following chronically elevated glucocorticoids, and how 
obesity status affects glucocorticoid-induced metabolic disease, focusing on effects in adipose 
and muscle.  
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Methods: To determine the impact of obesity on glucocorticoid associated metabolic disease, 
clinical measures and adipose tissue transcriptional changes were studied in lean and obese 
patients with Cushing’s disease.  To extend these findings, lean and obese mice were treated with 
dexamethasone and a variety of physiological and biochemical outcomes related to metabolic 
syndrome were assessed. To understand the contribution of the adipocyte glucocorticoid receptor 
(GR) in dexamethasone-induced metabolic disease, metabolic disease outcomes were measured 
in lean and obese GR knockout mice. Dexamethasone regulation of adipogenic genes was also 
assessed in adipocytes in order to determine potential GR targets during early adipogenesis, a 
process negatively associated with insulin resistance. Lastly, juvenile dexamethasone exposure 
studies were conducted in mice to determine how this affects body composition and glucose 
homeostasis in adulthood.   
Results: Obesity resulted in synergistic elevations of glucocorticoid-induced lipolysis, insulin 
resistance, NAFLD and muscle atrophy. Ablation of the adipocyte GR attenuated these effects, 
with the exception of muscle loss. In regards to dexamethasone-induced adipogenesis, Klf5 was 
induced early and in the absence of other stimuli, suggesting it may be a promising target for 
future study. Evidence of reduced glucose tolerance was observed in adult male and female mice 
following short-term juvenile exposure to dexamethasone. Reduced lean and fat mass was noted 
in dexamethasone-treated adult male mice, suggesting that male mice are more susceptible to 
adverse outcomes during this window of exposure. 
 
 
 xii 
Conclusion: Diet-induced obesity amplifies the adverse metabolic outcomes of glucocorticoids, 
such as insulin resistance and NAFLD, in humans and mice, as well as exacerbates muscle 
wasting in mice.  These data implicate adipose as a key tissue in glucocorticoid-induced systemic 
insulin resistance and NAFLD, though it is unclear how obesity is leading to greater 
dexamethasone-induced muscle wasting, and support that lipolysis is the most likely mediator 
linking adipocyte glucocorticoid action to metabolic disease. Additionally, short-term juvenile 
dexamethasone exposure was shown to disrupt normal glucose regulation in adult mice and had 
negative impacts on lean mass in male mice. Further studies focus on the specific mechanisms 
linking glucocorticoid signaling in adipocytes to insulin resistance, NAFLD and muscle health, 
as well as how obesity exacerbates these outcomes.  Future research is also warranted to fully 
elucidate the impact of childhood glucocorticoid exposure on metabolic health in adulthood. The 
findings presented here contribute to the greater body of research and could potentially be used 
to influence treatment strategies for those with elevated glucocorticoids.
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Chapter 1: Introduction 
Glucocorticoid function and regulation 
Glucocorticoids, also known as corticosteroids, are a class of steroid hormones whose main 
function is to maintain adequate glucose levels to the brain and other organs during times of 
starvation and stress (Kuo et al. 2015).  Glucocorticoids are necessary for proper physiological 
function and follows a circadian rhythm as well as through actions of the hypothalamus-
pituitary-adrenal (HPA) axis (S. M. Smith and Vale 2006; So et al. 2009).  Under normal 
physiological circumstances, glucocorticoids are highest in the morning with smaller peaks 
throughout the day and are lowest during sleep (Chan and Debono 2010).  Outside of the normal 
circadian rhythm, a stressful event or prolonged fasting can also activate the HPA axis. Initially 
there is a stimulus to the hypothalamus causing the release of corticotropin releasing hormone 
(CRH) in the median eminence of the brain.  CRH then binds and activates CRH-1 receptors on 
the anterior pituitary leading to the production and secretion of pro-hormone, 
proopiomelanocortin (POMC), that is then cleaved in to several hormones, including 
adrenocorticotropic hormone (ACTH).  ACTH is released into the bloodstream and acts on the 
MC2R receptors, located in the zona fasciculata region of the adrenal cortex to promote the 
synthesis and release of glucocorticoids (Molina 2013).  Under normal circumstances, 
glucocorticoids negatively feedback to the pituitary and hypothalamus to prevent excess 
glucocorticoid production.   
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Glucocorticoids are synthesized from cholesterol by way of multiple enzymatic conversion steps 
ultimately leading to the production of corticosterone, cortisone (also known as 11-
deoxycortisol) or cortisol.  Corticosterone is the active endogenous form of glucocorticoids in 
rodents; however, in humans, cortisol is the active endogenous form.  Cortisone is inactive, but 
can be interconverted with cortisol via 11b-hydroxylase (11-ßHSD) enzymes 1 and 2, 
respectively (Paterson et al. 2005).  These hydroxylase enzymes are key to the local tissue 
regulation of glucocorticoid activity.  Once released into the bloodstream, glucocorticoids, being 
fat-soluble molecules, are able to diffuse into the lipid membranes of any cell and can act in 
virtually all tissues given the widespread expression of the glucocorticoid receptor (GR).  The 
GR is the primary receptor for glucocorticoids; however, glucocorticoids are quite similar in 
their chemical structure to mineralocorticoids, another class of steroid hormones, and can 
activate the mineralocorticoid receptor (MR) as well.  Therefore, tissues that are important for 
blood pressure regulation, such as those found in the kidneys, express 11-ßHSD2 thereby 
inactivating cortisol (via conversion to cortisone) in effort to suppress cortisol-MR binding. The 
majority of metabolic tissues express higher levels of 11-ßHSD1 to allow for cortisol-GR 
binding and activity (Paterson et al. 2005). 
 
In order to elevate blood glucose when needed, glucocorticoids promote the breakdown of 
muscle and fat to provide substrates for gluconeogenesis via the transcriptional regulation of key 
genes.  As mentioned above, glucocorticoids are able to diffuse into cell membranes; once in the 
cell, glucocorticoids bind the GR in the cytosol, which allows for the translocation of the ligand-
receptor complex into the nucleus.  In the nucleus, the glucocorticoid-GR complex activates 
target genes by binding to a specific motif, known as glucocorticoid regulatory elements (GREs), 
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that can be located within or around that gene (J.-C. Wang et al. 2004; Reddy et al. 2009; Jolma 
et al. 2015).  Once bound, the GR can either suppress or promote transcription, depending on the 
gene.  In major metabolic tissues, such as the liver, adipose tissue and muscle, the GR activates 
genes involved in gluconeogenesis, adipocyte lipolysis and muscle atrophy, respectively, in order 
to support glucose production via gluconeogenesis in the liver.  
 
Induction of Adipocyte Lipolysis by Glucocorticoids 
Adipocyte lipolysis is the breakdown of tri-, di- and monoglycerides into their constitutive 
elements, glycerol and free fatty acids, and chronic elevation of these metabolites can lead to 
insulin resistance and fatty liver disease. There are several enzymes regulating adipose tissue 
lipolysis including adipose triglyceride lipase (ATGL; encoded by Pnpla2), hormone-sensitive 
lipase (HSL; encoded by Lipe), monoacylglycerol lipase (MGL; encoded by Mgll) lipoprotein 
lipase (LPL; encoded by Lpl) and perilipin (encoded by Plin) (Zechner et al. 2012).  Of these, 
Lipe/HSL and Pnpla2/ATGL have been suggested as potential GR targets in glucocorticoid 
activation of lipolysis. ATGL is primarily responsible for the breakdown of triglycerides into 
diglycerides via the removal of one fatty acid and is known as the rate limiting enzyme in 
lipolysis; however, some have proposed that at high levels it can hydrolyze all three 
acylglycerols (Jenkins et al. 2004; X. Yang et al. 2011).  HSL is the primary enzyme in 
diglyceride hydrolysis.  Both of these proteins require activation, CGI-58 is responsible for 
binding and activating ATGL, whereas PKA and AMPK are known to phosphorylate HSL on 
multiple serine sites leading to HSL activity.  
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Glucocorticoid-induced lipolysis is a well-known phenomenon that has been demonstrated in 
vitro and in vivo (Harvey et al. 2018; Xu et al. 2009; Djurhuus et al. 2004, 2002; Kršek et al. 
2005). Physiologically, the substrates produced from lipolysis can aid in hepatic 
gluconeogenesis. Glycerol is a non-carbohydrate precursor that can be converted into glucose, 
and fatty acids can be converted into acetyl-CoA which can activate pyruvate carboxylase, one 
rate limiting enzyme in gluconeogenesis. In addition, acetyl-CoA can provide energy for the 
costly production of glucose (Williamson, Kreisberg, and Felts 1966). We and others have 
shown that glucocorticoids lead to increased ATGL expression, HSL expression or both along 
with elevations of other markers of lipolysis, such as non-esterified fatty acids (NEFA; free fatty 
acids), glycerol and circulating catecholamines (Harvey et al. 2018; Xu et al. 2009; Djurhuus et 
al. 2004, 2002; Kršek et al. 2005; Hochberg, Harvey, et al. 2015).  However, the exact 
mechanisms leading to glucocorticoid activation of these enzymes, or their relative importance 
are yet to be fully understood.  One group has proposed that Pde3b, encoding a 
phosphodiesterase responsible for inactivation of cAMP, a key player in early activation of 
lipolysis, is down regulated (Xu et al. 2009), while others suggest that upregulation of 𝛽-
adrenergic receptors is what is leading to glucocorticoid-induced lipolysis (Lacasa, Agli, and 
Giudicelli 1988); however, these findings have not been confirmed by further study.  Elevated 
lipolysis can lead to ectopic lipid storage, such as is seen in non-alcoholic fatty liver disease and 
is associated with insulin resistance (Boden et al. 1995; Seppälä-Lindroos et al. 2002). 
Glucocorticoid-Dependent Regulation of Muscle Atrophy 
Glucocorticoids also promote catabolic effects in muscle. Muscle atrophy, also described as a 
decrease in muscle mass, is a consequence of excess glucocorticoids and when prolonged this 
can lead to muscle weakness and frailty (Blom et al. 2017; Barry and Gallagher 2003).  It is 
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likely glucocorticoid-induced muscle atrophy occurs to provide substrates for hepatic 
gluconeogenesis, similar to what I described with lipolysis above.  Indeed, proteolysis in the 
muscle leads to the generation of amino acids, substrates that feed into the gluconeogenic 
pathway. Glucocorticoids cause reduced muscle strength in children and adults, as well as 
enhanced leucine oxidation (Beaufrere et al. 1989; Blom et al. 2017; Barry and Gallagher 2003).  
Furthermore, there is evidence for glucocorticoid activation of muscle proteolysis (Price et al. 
1994; Wing and Goldberg 1993; D. Dardevet et al. 1995) and reduced protein synthesis (Long, 
Wei, and Barrett 2001; Menconi et al. 2007).  Mechanistically, glucocorticoids have been shown 
to upregulate genes involved in muscle atrophy, such as the atrogenes, Fbxo32 and Trim63, 
encoding the proteins MuRF-1 and Atrogen-1 respectively (Hochberg, Harvey, et al. 2015) as 
well as the FoxO proteins (X Wang et al. 2017).  With muscle health being pertinent to overall 
physical fitness, it is important to understand the impact of excess glucocorticoids in muscle. 
 
Glucocorticoids Promote Adipogenesis 
While glucocorticoid induce catabolic actions on muscle and adipose tissue resulting in the flux 
of amino and fatty acids to other tissues, they also play an essential role in the formation of new 
adipocytes, especially in vitro (Chapman, Knight, and Ringold 1985; Hartman et al. 2018).  
Adipogenesis is a complex process and while much is known regarding the genes involved, there 
is still much to unravel as to how these genes are regulated.  PPAR𝛾 along with C/EBP proteins 
(𝛼, 𝛽	𝑎𝑛𝑑	𝛿) are key proteins in early adipogenesis and are termed the ‘master regulators’ of 
adipocyte differentiation. C/EBP𝛿	and	C/EBP𝛽	are expressed first in the process and are 
responsible for the activation of PPAR𝛾. PPAR𝛾 leads to C/EBP𝛼 expression and these two 
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proteins are involved in a positive feedback loop, see review (Lefterova and Lazar 2009).  
Upregulation of the aforementioned genes and proteins happens in the first several hours 
following the addition of adipogenic cocktail, which typically includes insulin, IBMX and 
dexamethasone.  Though the requirement of glucocorticoids in the differentiation is evident, as 
removal of glucocorticoids or GR antagonism prevents lipid accumulation and differentiation 
(Chapman, Knight, and Ringold 1985; Hartman et al. 2018), the mechanisms governing this 
process remain unclear.  Several gene targets have been proposed as potential GR targets during 
adipogenesis including Cebpd, Nfil3, Dexras1 and Ccar1 (Y. Yang et al. 2017; Cha et al. 2013; 
Ou et al. 2014; Cao, Umek, and McKnight 1991) as well as multiple members of the Kruppel-
like family proteins (Wu and Wang 2013).  Adipogenesis is important in normal development 
and has shown to be beneficial for glucose homeostasis (S. Y. Kim et al. 2011); therefore, it is 
important to determine the exact role of glucocorticoids in this process.  
 
The combined effects on lipolysis, proteolysis and adipogenesis cause a constellation of acute 
and chronic metabolic effects.  The comorbidities and metabolic processes associated chronically 
elevated glucocorticoids, such as muscle wasting, insulin resistance, increased fat mass, lipolysis 
and NAFLD are well known; however, the underlying mechanisms that lead to these side effects 
have not been fully elucidated.  Moreover, the effect of obesity on glucocorticoid-induced 
metabolic disease had never been evaluated.   
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Causes and physiological relevance of glucocorticoid excess 
Systemic glucocorticoids levels are tightly regulated under normal conditions governed by 
endogenous signals including circadian rhythm and negative feedback, as mentioned above.  
However, there are a variety of conditions by which glucocorticoid regulation is disrupted and 
there is even evidence to suggest that disruption even at an early age can lead to impact a variety 
of psychological and metabolic outcomes later in life (Wilson et al. 2015; Chow et al. 2007; Van 
Dongen-Melman et al. 1995; Tangalakis et al. 1992; Khalife et al. 2013; De Blasio et al. 2007), 
indicating short-term disruption during key developmental windows can lead to long-term 
consequences.  Glucocorticoid elevation can happen as a result of stress, this is evidenced by 
elevated cortisol levels individuals who feel helpless (Müller 2011) or exposed to multiple other 
types of stress such as public speaking and achievement tasks (Nater et al. 2005; Kirschbaum, 
Wust, and Hellhammer 1992), and animal stress exposure studies indicate chronic social stress 
leads to elevations in cortisol and possibly influences CRH binding (Jöhren, Flügge, and Fuchs 
1994; Flügge 1995), which can lead to disruptions in normal circadian rhythm. 
 
Conditions in which there is excessive glucocorticoid levels fall under the diagnosis of Cushing’s 
syndrome.  Cushing’s syndrome is the umbrella term used to describe the symptoms arising from 
prolonged glucocorticoid elevations and encompasses a multitude of conditions including ectopic 
cortisol-producing tumors, Cushing’s disease and prescribed therapeutics.  Cushing’s disease is a 
caused by a pituitary tumor that constitutively secretes ACTH, thereby overriding the negative 
feedback system and ultimately resulting in a constant overproduction of cortisol.   
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Glucocorticoids are frequently medically prescribed to treat many serious autoimmune and 
inflammatory conditions, such asthma, cancer, COPD, lupus and rheumatoid arthritis, as they are 
potent anti-inflammatory agents.  Commonly prescribed glucocorticoids include prednisone, 
prednisolone, cortisone, corticosterone, hydrocortisone, betamethasone and dexamethasone, to 
name a few.  The main distinction among these drugs is that some activate the glucocorticoid and 
mineralocorticoid receptors; whereas others are specific to the glucocorticoid receptor. The 
majority of data provided here are following dexamethasone treatment, a potent synthetic 
glucocorticoid specific to the glucocorticoid receptor potentially limiting the relevance of these 
findings. Though Cushing’s disease is rare (Lindholm et al. 2001), Cushing’s syndrome due to 
medication is quite common with an estimated 1-3% of developed populations being prescribed 
glucocorticoids at any given time (Overman, Yeh, and Deal 2013; Fardet, Petersen, and Nazareth 
2011; Hsiao et al. 2010; Laugesen et al. 2017).  Individuals with Cushing’s syndrome are prone 
to insulin resistance, non-alcoholic fatty liver disease (NAFLD), muscle wasting and 
hypertension, as well as increased fat and abnormal distribution of fat mass.  It is important to 
note that the majority of the research surrounding side effects from chronically elevated 
glucocorticoids has been assessed in mostly lean populations, as synthetic glucocorticoids were 
developed and approved in the mid-1900s.  Today, there is a growing epidemic of obesity, with 
glucocorticoids still being widely prescribed.   
 
Glucocorticoid Excess as a Public Health Issue 
 
Considering the variety of conditions requiring corticosteroid treatment, combined with the 
prevalence of chronic stress, there is a sizable number of individuals, young and old, lean and 
obese that are exposed to elevated glucocorticoids. Epidemiologic studies reviewing prevalence 
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of chronic stress and glucocorticoid use demonstrate the impact of excess glucocorticoids on 
public health. For example, a national representative study in 2006 reported that an estimated 
6.4% of working Americans meet the criteria for Major Depressive Disorder (R. R. C. Kessler et 
al. 2006) with depression being shown to lead to elevated cortisol levels throughout the day in 
humans (Dienes, Hazel, and Hammen 2103), and 7.8% of Americans suffering from Post-
Traumatic Stress Disorder (R. Kessler et al. 1995).  Stress is a known stimulus of HPA axis 
leading to increased cortisol production, as such glucocorticoids are commonly referred to as 
stress-induced hormones. Stress is an interesting psychological condition as it can be brought on 
by any number of things and effects people in different ways, mentally and physically (Gradus 
2017); as a result, stress levels among the general population are difficult to measure. However, 
there are several reports that highlight the significance of elevated stress levels across developed 
countries by highlighting the prevalence common stress disorders such as of PTSD, anxiety and 
depression (Stansfeld and Candy 2006; Wiegner et al. 2015; R. Kessler et al. 1995).   
 
Cushing’s syndrome encompasses a variety of conditions leading excess glucocorticoids. 
Cushing's disease is among the conditions of Cushing’s syndrome, and results from a pituitary 
adenoma that secretes ACTH, leading to elevated cortisol production.  Cushing’s disease is quite 
rare, with an estimated annual incidence of 1.2–2.4 per million across inhabitants of Spain and 
Denmark (Lindholm et al. 2001; Etxabe and Vazquez 1994) and an estimated annual incidence 
of 6.9–7.6 cases per million in the US (Broder et al. 2015).  Cortisol-secreting adrenal tumors are 
even less common with an estimated 0.2–0.6 cases per million (Lindholm et al. 2001).  As 
mentioned above, though endogenous forms of Cushing’s syndrome are rare, Cushing’s 
syndrome brought on by exogenous glucocorticoid administration is quite common with an 
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estimated of 1-3% of US, UK and Danish populations being prescribed some form of 
corticosteroid treatment at any given time (Overman, Yeh, and Deal 2013; Fardet, Petersen, and 
Nazareth 2011; Hsiao et al. 2010; Laugesen et al. 2017). 
 
Given the high prevalence of corticosteroid treatment, there are a couple of important factors to 
consider.  The first is the rationale for which individuals being prescribed these drugs.  
Glucocorticoids are effective and potent anti-inflammatory drugs, as such they are prescribed to 
treat many inflammatory and autoimmune diseases, as well as cancer.  To date, they are the best 
available and approved drugs for this type of treatment (Becker 2013).  In this context, 
glucocorticoids are life-saving, or at least life-extending, to many disease populations, and will 
continue to be prescribed to considerably sick individuals.  The second consideration is for the 
special populations being administered glucocorticoids, which include pregnant women, 
children, elderly individuals and people with obesity.  There is considerably less data on the 
effects of chronically elevated glucocorticoids in these populations, but again the use is 
widespread.   
 
Prenatal Glucocorticoid Exposure and Fetal Outcomes 
 
 
Glucocorticoids are often prescribed to pregnant women when there is a high risk of preterm 
birth, as glucocorticoids are vital to development of the fetus.  Indeed, maternal glucocorticoid 
treatment has been shown to prevent a variety of adverse events in in preterm infants such as 
respiratory distress syndrome (R. Ballard and Ballard 1976), as well as reduced morbidity and 
mortality risk in premature infants and other benefits to the fetus, see review (Braun et al. 2013).  
Though it is difficult to find reports of overall prevalence, one study monitored prescriptions 
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among pregnant women across multiple facilities in the US over a four-year period and found 
that out of the 150 thousand plus recorded births, 3.9% of these women were given some form of 
glucocorticoids (Andrade et al. 2004).  Outside of maternal exposure to exogenous 
glucocorticoids, added stress during pregnancy can increase the mother’s cortisol levels, which 
has been observed in cases of severe morning sickness and lead to undernutrition (Ünsel, Benian, 
and Tamer Erel 2004; Kauppila, Jarvinen, and Haapalahti 1976). 
 
Though essential for at risk births, prenatal glucocorticoid exposure has been reported to have 
negative consequences on the fetus such as increased blood pressure (Tangalakis et al. 1992),  
psychological abnormalities (Khalife et al. 2013) and has been shown to alter global DNA 
methylation in fetus that persists to further generations in guinea pigs (Crudo et al. 2012); though 
the implications for DNA methylation findings are not fully understood at this time. 
Metabolically speaking, maternal exposure is associated with impaired beta cell development 
and insulin content (Blondeau et al. 2001) and as well as glucose homeostasis disturbances (De 
Blasio et al. 2007; de Vries et al. 2007) in animals.  Furthermore, one study in Denmark reported 
a 20% increase in Type 1 diabetes and a 51% increase in Type 2 diabetes in human offspring 
from prenatally-exposed mothers when compared to unexposed mothers (Greene et al. 2013). 
 
Glucocorticoid Exposure in and Children 
 
 
Glucocorticoid treatment is common among children with juvenile inflammatory arthritis (JIA) 
(Hansen et al. 2014), asthma (Arabkhazaeli et al. 2016) and cancer (Pufall et al. 2015).  Though 
childhood cancer and JIA are considered rare in the US, with an estimated 10,270 new diagnoses 
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in 2017 for cancer (Siegel, Miller, and Ahmedin 2017) and an estimated 11.7 cases per 
100,000/yr for JIA (Peterson et al. 1996), asthma is more common with an estimated childhood 
prevalence of 8.3% (CDC 2016).  Previous studies have also indicated potential increased risk of 
adult obesity in children exposed to glucocorticoids (Aljebab, Choonara, and Conroy 2017), 
though other studies have not found this to be the case (Belle et al. 2018).  These conflicting 
reports are likely due to all the confounding variables associated with childhood cancer aside 
from glucocorticoid treatment. In Chapter 4, obesity and other metabolic outcomes will be 
assessed in adult mice following juvenile dexamethasone treatment to expand on these human 
findings.   Other assessments of body composition changes due to childhood glucocorticoid 
exposure include those investigating outcomes in bone and muscle.  There are data that show 
children on chronic glucocorticoid treatment have lower bone mineral density and are at a higher 
risk for fractures compared to healthy controls (Hansen et al. 2014).   Interestingly, 
glucocorticoids have been shown to improve muscle strength and function in children with 
muscular dystrophy, though the mechanism for this is unclear, it is suggested that this is partially 
due to the anti-inflammatory effects of the drug (Petnikota et al. 2016); therefore, it is unclear 
whether the same would be true of healthy children.  Analogous to prenatal treatment, 
glucocorticoid treatment in children often leads to hypertension (Kamdem et al. 2008; Magiakou 
1997); however, in the case of pediatric Cushing’s patients this was reversed in as little as three 
months following tumor removal.  Moreover, hyperglycemia and insulin resistance are common 
occurrence following childhood glucocorticoid exposure (Aljebab, Choonara, and Conroy 2017; 
Chow et al. 2013).  Glucose homeostasis will also be assessed in Chapter 4 to determine if this 
finding is altered in adult mice following juvenile dexamethasone exposure. 
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Prevalence and Implications of Excess Glucocorticoids in the Elderly 
 
 
Given the evidence for glucocorticoid-induced muscle atrophy, the contribution to metabolic 
disease and the immunosuppressive nature of these drugs, elevated glucocorticoids may have the 
largest influence on geriatric health.  Elderly individuals are commonly prescribed 
glucocorticoids for issues such as COPD (Fardet, Petersen, and Nazareth 2011) with close to 
roughly 10% of COPD-diagnosed elderly individuals in the US (Akinbami LJ 2011), 
glucocorticoids are also commonly prescribed for other issues common to elderly individuals 
such as inflammatory bowel disease (Parian and Ha 2015).  To put this into perspective, the 
prevalence for glucocorticoid use are highest for elderly populations with an estimated 2.7% of 
elderly women and 3.5% of elderly men in the US reported use of glucocorticoids, and an 
alarming 10% of the elderly population of Denmark reported use (Overman, Yeh, and Deal 
2013; Laugesen et al. 2017). Not surprisingly, several studies of glucocorticoid use show 
evidence of association with osteoporosis, hypertension and diabetes in this population (S. Y. 
Kim et al. 2011; Ben Dhaou et al. 2012; Baldwin and Apel 2013).  The added risk of 
osteoporosis and fractures (Van Staa et al. 2000) is arguably of the highest concern with this 
population being prone to falls and are known to have increased risk for sarcopenia (Dutta and 
Suppl 1997). Furthermore, as I have previously shown, glucocorticoid-induced muscle loss is 
greater in obesity and there is an increase of sarcopenic obesity in the elderly population  
(Johnson Stoklossa et al. 2017) potentially putting these individuals at an even greater risk of 
overall frailty. 
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Prevalence of Obesity and Glucocorticoid Use 
 
 
As previously mentioned, obesity is a major problem in the US, and is becoming a worldwide 
epidemic. Most recent reports of estimate that 13% of adults have obesity and 39% of adults 
being overweight (WHO 2016); in addition, it is reported that over one-third of the geriatric 
population (ages 65 and over) has obesity (CDC 2012). Furthermore, childhood obesity is rising 
rapidly with a reported 18.5% of children ages 2-19 having obesity (Hales et al. 2017).  Given 
the prevalence of obesity, combined with that of glucocorticoid use in developed countries across 
all ages, it is likely that many individuals are exposed to both.  This may be exacerbated by local 
activation of cortisol in obesity (Livingstone et al. 2016). The combination of obesity and excess 
glucocorticoids is understudied; however, given my findings presented in Chapter 2, it appears 
that glucocorticoids in the presence of obesity is quite detrimental to metabolic health in both 
mice and humans.  In support of this, Riddell and colleagues have reported that providing HFD 
and glucocorticoids in concert to young and adult rats, prior to the onset of obesity also resulted 
in hyperglycemia, insulin resistance and NAFLD (D’souza et al. 2012; Beaudry et al. 2013; 
Shpilberg et al. 2012).  Future studies should investigate the effect of genetic obesity in concert 
with excess glucocorticoids to determine whether these findings are more attributable to diet or 
obesity status.  
 
The literature on glucocorticoid exposure in the populations presented above is likely influenced 
by multiple confounders including reason for treatment. However, it is apparent that there is a 
sufficient number of individuals exposed to excess glucocorticoids and much evidence to suggest 
that these drugs have a significant impact on overall health.  Therefore, excess glucocorticoids 
may pose a threat to public health, warranting further exploration with controlled study design to 
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account for the actual effects of glucocorticoids in individuals of all ages.  We will explore the 
effects of obesity on glucocorticoid-induced metabolic disease in humans and mice in Chapter 2. 
 
This dissertation describes my work to evaluate the underlying mechanisms that contribute to the 
observed glucocorticoid-induced metabolic dysfunction, as well as the effect of obesity on these 
outcomes.  Here I evaluate chronically elevated glucocorticoids in humans, cell and rodent 
models examining the direct and indirect effects of glucocorticoids on metabolism.  Specifically, 
in Chapter 2, using novel mouse models of Cushing’s, I highlight the metabolic consequences of 
elevated glucocorticoids and make the case that glucocorticoid-induced lipolysis, insulin 
resistance and NAFLD are exacerbated in the presence of obesity.  In Chapter 3, I evaluate the 
role of glucocorticoid signaling in adipocytes including the induction of adipogenesis, as well as 
the contribution of adipocyte GR to glucocorticoid-induced metabolic disease. In Chapter 4, I 
describe studies related to the involvement of glucocorticoids on muscle atrophy and glucose 
homeostasis in a novel juvenile mouse model and in adult mice, as well as the modifying effects 
of obesity on muscle degradation in adult mice. Taken together, these data have provided novel 
insights into the underlying metabolic processes and molecular mechanisms leading to 
glucocorticoid induced insulin resistance and fatty liver disease, as well as the modifying effects 
of obesity.  
 
  
 
 
 16 
 
Chapter 2-Glucocorticoid-induced metabolic disturbances are 
exacerbated in obesity 
Introduction 
The data described here are partially adapted from (Harvey et al. 2018; Hochberg, Harvey, et al. 
2015).  Glucocorticoids are important for proper glucose homeostasis during stress or fasting, but 
can lead to symptoms similar to those seen in metabolic syndrome if elevated for prolonged 
durations.  Cushing’s syndrome encompasses a variety of conditions which manifest in response 
to chronically elevated levels of glucocorticoids, including exogenous corticosteroid treatment as 
well as endogenous overproduction of cortisol, and is often associated with changes in adipose 
mass and distribution, non-alcoholic fatty liver disease (NAFLD) and impaired glucose tolerance 
(Paredes and Ribeiro 2014).  Cushing’s disease, or persistently high circulating levels of cortisol 
secondary to a pituitary adenoma, leads to significant truncal obesity and diabetes (Cushing 
1932).  Obesity and diabetes are major factors in morbidity and mortality in Cushing’s disease 
(Ntali, Grossman, and Karavitaki 2015).  Cushing's disease is very rare, with an incidence of 
1.2–2.4 per million (Lindholm et al. 2001), but iatrogenic Cushing's syndrome, caused by 
chronic glucocorticoid treatment, is very common and leads to similar clinical manifestations.  It 
is estimated that at any given time 1-3% of the US, UK and Danish populations are prescribed 
exogenous corticosteroids, which may increase their risk for developing the associated metabolic 
complications (Overman, Yeh, and Deal 2013; Fardet, Petersen, and Nazareth 2011; Hsiao et al. 
2010; Laugesen et al. 2017).    
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Numerous studies have shown that glucocorticoids have profound effects on adipose tissue 
metabolism, including promotion of adipocyte differentiation (Hauner, Schmid, and Pfeiffer 
1987) and induction of lipolysis and lipogenesis (Samra et al. 1998; Campbell et al. 2011; 
Divertie, Jensen, and Miles 1991; Kršek et al. 2006).  Glucocorticoids, through binding to the 
glucocorticoid receptor, exert transcriptional induction and repression of numerous genes (Reddy 
et al. 2009; Surjit et al. 2011).  Despite the widespread chronic glucocorticoid exposure, there 
have been no human in vivo studies on global gene expression changes in adipose tissue in 
response to long-term exposure to glucocorticoids.  
 
Similar to Cushing’s, obesity is accompanied by a multitude of metabolic disturbances, such as 
insulin resistance and NAFLD, and is a worldwide epidemic (The GBD 2015 Obesity 
Collaborators 2017).  Comparing the high rates of medically prescribed corticosteroids with the 
prevalence of overweight and obesity in developed countries, the combination of obesity and 
glucocorticoid excess may be present in many individuals.  Given the similar co-morbidities 
associated with obesity and chronically elevated glucocorticoids, we hypothesized that the 
combinations of these two conditions would lead to worse metabolic outcomes than either of 
them alone.  This is supported by studies in rats showing that corticosterone and high-fat diets 
combine to cause worsened insulin resistance and non-alcoholic fatty liver disease (Beaudry et 
al. 2013; Shpilberg et al. 2012).   
To study the effect of excess endogenous glucocorticoids on adipose tissue, we used RNA 
sequencing of adipose tissue biopsies from Cushing's disease patients and controls with non-
secreting adenomas. We found a distinctive pattern of changes in many transcripts that are highly 
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associated with Cushing's disease. Many of these genes explain previously observed metabolic 
effects of excess glucocorticoids described in vitro, in both animal models and in humans.  These 
include enhanced fatty acid and triglyceride biosynthesis, protein degradation, activation of 
glycolysis and reductions in immune responses. We were able to confirm many of these findings 
by treating mice with dexamethasone for several weeks. 
 
To investigate the modifying effects of obesity on glucocorticoid-induced metabolic disease, we 
stratified the patients based on their BMI and found exacerbated effects of joint obesity and 
Cushing’s disease. To evaluate this further, I developed a novel mouse model system with diet-
induced obesity followed by glucocorticoid exposure.  Using this system, I measured a variety of 
metabolic outcomes. There is an array of physiological changes that occur as a result of elevated 
glucocorticoids including increased fat mass (Hochberg, Harvey, et al. 2015; Abad et al. 2001; 
Geer et al. 2010), NAFLD (Shpilberg et al. 2012) and increased lipolysis (Djurhuus et al. 2004; 
Kršek et al. 2005; Djurhuus et al. 2002), all of which have been associated with decreased insulin 
sensitivity (Zhang et al. 2015; Boden et al. 1995; Seppälä-Lindroos et al. 2002).   
 
Recent tissue-specific knockouts of glucocorticoid signaling mediators had implicated adipose 
tissue as a central node linking glucocorticoid action and lipolysis to systemic insulin resistance 
and NAFLD (Mueller et al. 2017; Shen et al. 2017; S. A. Morgan et al. 2014; Y. Wang et al. 
2014).  Here I present the finding that chronically elevated glucocorticoids, via dexamethasone 
treatment, in the presence of diet-induced obesity have synergistic effects on lipolysis, insulin 
resistance and fatty liver disease.  Obese dexamethasone-treated mice have reduced fat mass 
compared to all other groups, yet have hyperglycemia and severe insulin resistance.   Therefore, I 
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hypothesized that glucocorticoid-induced adipocyte lipolysis drives insulin resistance in obese 
animals. 
Methods 
Patient Recruitment 
The study was approved by the institutional review board of the University of Michigan Medical 
System.  Written informed consent was obtained from all patients.  Patients were recruited 
consecutively from those undergoing transsphenoidal adenomectomy at the University of 
Michigan for Cushing's disease or non-functioning pituitary adenoma over a 12-month period.   
Exclusion criteria were age <18, current hormone treatment including glucocorticoids, 
malignancy, inflammatory disease, diabetes type 1 and established pituitary hormone 
deficiencies.  For each patient, a data sheet was completed including, age, sex, anthropometric 
measurements, diagnosis of hypertension, diabetes, results of blood tests and medications.  
Fasting blood samples were assayed for glucose (Siemens Advia 1800) and insulin (Life 
Technologies) as instructed by the manufacturers.  Patient recruitment and tissue collection was 
co-ordinated by my collaborator Dr. Irit Hochberg. 
 
Subcutaneous Fat Biopsy 
During the course of pituitary surgery, a routine subcutaneous fat graft for sealing the surgical 
field is taken immediately after anesthesia, but before glucocorticoid treatment.  Approximately 
500 mg of this fat graft was used in this study with ~100 mg fresh adipose tissue was utilized for 
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ex vivo lipolysis assay and ~200 mg snap frozen in liquid nitrogen and stored at -80 °C for RNA 
preparation and ceramide analysis.   
 
Human Transcriptomic Analysis 
Total RNA was extracted from adipose tissue using the RNEasy kit (Qiagen) and its quality was 
verified using the Agilent 2100 Bioanalyzer (Agilent Technologies).  At the University of 
Michigan DNA Sequencing Core, cDNA libraries from polyA mRNA were prepared using 
TruSeq cDNA synthesis kit and sequenced using a HiSeq 2000 (Illumina).  Samples were run on 
2 lanes of a HiSeq 2000 (Illumina) generating 8,612,682 to 16,469,501 single-ended 50 bp reads 
per sample.   These were aligned to the human genome (Enembl GRCh37.74, Genbank 
Assembly ID GCA_000001405.14) using TopHat version 2.0.10 (D. Kim et al. 2013), Bowtie 2 
version 2.1.0 (Langmead and Salzberg 2012) and Samtools version 0.1.18.  Reads were mapped 
to known genes using HTseq (Anders, Pyl, and Huber 2014).   Gene expression was analyzed 
using DESeq2 version 1.2.10 (Love, Huber, and Anders 2014).  These subjects corresponded to 
the patients described in Table 2, with the exception of subjects 29 and 31 (both Cushing's 
disease patients), which had clinical data but no RNAseq data.  RNAseq analyses were 
performed by my collaborator Dr. Quynh Tran. 
 
Animal Procedures 
Twenty-four C57BL/6 adult male mice were purchased from The Jackson Laboratory (stock 
#000664) at nine weeks of age.  Following a one-week acclimation period, mice were either 
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treated with 1 mg/kg/day of dexamethasone (Sigma-Aldrich) in their drinking water (N=12) or 
used as controls (N=12).  All animals were on a light dark cycle of 12/12 h and housed at 22°C.   
Following a week of acclimation, mice were placed on diets or treated with dexamethasone as 
described in the figure legends.  Mice were treated with vehicle (water) or approximately 
1mg/kg/d of water-soluble dexamethasone (Sigma-Aldrich; catalog #2915), a synthetic 
glucocorticoid, dissolved in their drinking water for 12 weeks.  Additional cohorts of mice used 
in these experiments either remained on a standard diet (normal chow diet; NCD; 5L0D LabDiet; 
13% fat; 57% carbohydrate; 30% protein) or were provided a high fat diet (45% fat from lard; 
35% carbohydrate mix of starch, maltodextrin and sucrose; 20% protein from casein; cat# 
D12451) for either 8 or 12 weeks followed by dexamethasone treatment.  Mice were group 
housed with four mice per cage and food consumption was measured weekly by weight 
reductions per cage and calculated to reflect estimated intake of each mouse per day in a given 
cage.  Mice remained on their respective diets for the duration of the study.  All mice were 
provided with access to food and water ad libitum throughout the study, unless otherwise noted.   
 
Water intake was measured weekly to determine the concentrations of dexamethasone consumed 
per cage.  Average concentration per mouse was estimated by accounting for number of mice in 
the cage.  For the longer, six-week dexamethasone treatments, 16 HFD-fed, dexamethasone-
treated mice appeared ill and were euthanized and thus removed from all analyses once 
symptoms were noticed.  Symptoms included lethargy, weight loss and evidence of pancreatitis 
in some of the mice.  Animal body weight and composition was determined weekly using a 
digital scale and EchoMRI 2100, respectively.  Body weight quickly stabilized following 
removal from the CLAMS in both groups.  At the end of treatment, all cohorts of mice were 
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fasted for 16 h beginning a ZT10, dexamethasone water was not removed during this time, and 
euthanized by cervical dislocation after isoflurane anesthesia at ZT3 of the following day.  
Immediately following euthanasia, mice were dissected and the right inguinal white adipose 
tissue (iWAT) and epididymal white adipose tissue (eWAT) depots were carefully removed and 
weighed.  Adipose tissues, along with a section of the left lateral lobe of the liver were snap 
frozen in liquid nitrogen for later analysis.  Small pieces of tissues were fixed in 10% phosphate-
buffered formalin for histology.  Animal procedures were approved by the University of 
Tennessee Health Science Center and University of Michigan Institutional Animal Care and Use 
Committees. 
 
Determination of Serum Dexamethasone 
 Serum from 16-hour fasted lean and obese mice following six weeks of dexamethasone 
treatment was acquired prior to euthanizing at the end of the study and sent to the University of 
Michigan Pharmacokinetic and Mass Spectrometry Core for LC-MS analysis of dexamethasone 
concentration.  Dexamethasone standard was used to make a calibration curve from 2.5 to 100 
ng/mL.  A separate weighing of dexamethasone was used to make quality control standards at 3 
and 30 ng/mL.  Quality control standards were run in triplicate before and during sample 
analysis.  For each calibration standard and quality control standard, 10 µL of blank plasma, 10 
µL of calibration or QC standard, and 40 µL of internal standard were mixed in a 96-well plate.  
Each analytical sample was prepared by mixing 10 µL mouse plasma, 10 µL acetonitrile and 40 
µL internal standard into a well of a 96-well plate.  Some samples were below 10 µL in volume.  
In these cases, the volume collected was diluted to 10 µL and prepared in the same manner as the 
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other samples.  The plate was mixed at 1000 rpm for 5 min, then centrifuged at 3500 rpm for 10 
min.  Four microliters of supernatant were injected for analysis onto a Waters Xevo TQD triple 
quadrupole UPLC mass spectrometer for analysis. 
 
 
Insulin Tolerance Tests and Hyperinsulinemic Euglycemic Clamp Experiments 
Insulin responsiveness was assessed via an insulin tolerance test (ITT).  Following a six-hour fast 
beginning at ZT1, mice were given an intraperitoneal (IP) injection of insulin (Humulin R, Lilly) 
as described in figure legends.  Blood was collected from the tail at basal and 15-minute intervals 
post-injection and glucose was determined using a One Touch Ultra Glucometer (Lifescan).   
 
For the hyperinsulinemic euglycemic clamp experiments, done by the University of Michigan 
Metabolism, Bariatric Surgery and Behavior Core under the direction of Dr. Nathan Qi and 
Melanie Schmitt, C57BL/6J adult (70d) male mice were fed HFD for eight weeks and treated 
with dexamethasone in their drinking water for three weeks or regular drinking water.  Animals 
were anesthetized with an IP injection of sodium pentobarbital (50−60 mg/kg).  Indwelling 
catheters were inserted into the right jugular vein and the right carotid artery, respectively.   The 
free ends of catheters were tunneled subcutaneously and exteriorized at the back of the neck via a 
stainless-steel tubing connector (coated with medical silicone) that was fixed subcutaneously 
upon closure of the incision.  Animals with healthy appearance, normal activity, and weight 
regain to or above 90% of their pre-surgery levels were used for the study.  Experiments were 
carried out in conscious and unrestrained animals using techniques described previously 
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(McGuinness et al. 2009; Ayala et al. 2006; Halseth et al. 1999).  Briefly, the primed (1.0 uCi)-
continuous infusion (0.05 uCi/min and increased to 0.1 µCi/min at t = 0) of [3-3H] glucose (50 
µCi/ml in saline) was started at t = -120min.  After a five-hour fast, the insulin clamp was 
initiated at t = 0, with a prime-continuous infusion (40 mU/kg bolus, followed by 8.0 
mU/kg/min) of human insulin (Novo Nordisk).  Euglycemia (120~130 mg/dL) was maintained 
during the clamp by measuring blood glucose every 10 min and infusing 50% glucose at variable 
rates, accordingly.   Blood samples were collected from the right carotid artery at t = 80, 90, 100, 
and 120 min for determination of glucose specific activity.   Blood insulin concentrations were 
determined from samples taken at t = -10 and 120 min.  A bolus injection of [1-14C]-2-
deoxyglucose ([14C]2DG; PerkinElmer) (10 µCi) was given at t = 120 min.  Blood samples were 
taken at 2, 5, 10, 15, and 25 min after the injection for determination of plasma [14C]2DG 
radioactivity.  At the end of the experiment, animals were anesthetized with an intravenous 
injection of sodium pentobarbital and tissues were collected and immediately frozen in liquid 
nitrogen for later analysis of tissue [1-14C]-2-deoxyglucose phosphate ([14C]2DGP) radioactivity.  
Blood glucose was measured using an Accu-Chek glucometer (Roche, Germany).  Plasma 
insulin was measured using the Linco rat/mouse insulin ELISA kits.   For determination of 
plasma radioactivity of [3-3H]glucose and [1-14C]2DG, plasma samples were deproteinized with 
ZnSO4 and Ba(OH)2 and counted using a Liquid Scintillation Counter (Beckman Coulter LS6500 
Multi-purpose Scintillation Counter).  Glucose turnover rate, hepatic glucose production and 
tissue glucose uptake were calculated as described elsewhere (Kraegen et al. 1985; Ayala et al. 
2006; Halseth et al. 1999). 
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Serum Glycerol and Fatty Acid Determination 
Following 12 weeks of dexamethasone treatment, 22-week-old ad libitum chow fed C57BL/6J 
male mice were anesthetized with isoflurane and blood was collected into heparin-coated 
capillary tubes via retro orbital bleed both prior to and 15 minutes following intraperitoneal 
injection of 10mg/kg isoproterenol (Sigma-Aldrich; catalog #I6504-1G) in Dulbecco’s 
phosphate-buffered saline (Thermo Fisher; catalog #BW17512F1).  Serum from these mice, as 
well as from a cohort of 28-week old mice on either HFD or chow, six-weeks post-
dexamethasone treatment was collected following an overnight fast beginning at ZT10.  For the 
human samples 25 mg pieces of adipose tissue were pre-incubated for 15 minutes in KRBH 
buffer (sigma) at 37 °C and then incubated for 1 hour at 37 °C in 300 ml KRBH in duplicate.  
Glycerol was assessed via Serum Triglyceride Determination Kit (Sigma-Aldrich; catalog 
#TR0100-1KT) and fatty acids were quantified using the HR Series NEFA-HR(2) kit (Wako 
Diagnostics; catalog #276-76491), in accordance with manufacturer’s guidelines. 
 
Cell culture 
3T3-L1 fibroblasts (pre-adipocytes; ATCC; authenticated via STRS analysis) were cultured in 
10% newborn calf serum, Dulbecco's Modification of Eagle's Medium (DMEM; 4.5 g/L D-
glucose; Fisher Scientific; catalog #11965118) with penicillin, streptomycin and glutamine 
(PSG) until confluence.  Cells were switched to a differentiation cocktail at two days post 
confluence (250nM dexamethasone, 500 uM 3-isobutyl-1-methylxanthine and 1ug/mL insulin in 
10% fetal bovine serum, in 4.5g/L glucose DMEM with PSG) for four days (Chiang S, Chang L 
2006).  Media was replaced with differentiation medium containing only insulin for an additional 
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three days.  For the following three days, cells remained in media with no additional treatment.  
Cells used for these experiments were not cultured beyond 22 passages.  To assess markers of 
lipolysis, cells remained in media and were treated with ethanol (vehicle) or 250nM 
dexamethasone for five days before lysing, with dexamethasone media being refreshed on day 
three and extracted on day five. 
 
Assessment of Triglyceride Content in Cells and Tissue 
3T3-L1 cells were grown and treated as described above.  At the end of the treatment period, 
cells were lysed in homogenization buffer (50 mM Tris pH 8, 5 mM EDTA, 30 mM Mannitol, 
protease inhibitor) and subjected to three freeze thaw cycles with liquid nitrogen, thawed at room 
temperature.  Frozen liver tissue was homogenized using a TissueLyser II (Qiagen).  Lipids were 
extracted using a chloroform:methanol (2:1) extraction.  Triglyceride content was assessed using 
the Serum Triglyceride Determination Kit and absorbance was detected as described in (Lu et al. 
2014). 
 
mRNA Extraction and Analysis 
Cells and tissues were lysed in TRIzol using the TissueLyser II, as decribed above, and RNA 
was extracted using a PureLink RNA kit (Life Technologies; catalog #12183025).  cDNA was 
synthesized from 0.5-1ug of RNA using the High Capacity Reverse Transcription Kit (Life 
Technologies; catalog #4368813).  Primers, cDNA and Power SYBR Green PCR Master Mix 
(Life Technologies; catalog #4368708) were combined in accordance with the manufacturer’s 
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guidelines and quantitative real-time PCR (qPCR) was performed as previously described (Lu et 
al. 2014) using the QuantStudio 5 (Thermo Fisher Scientific). mRNA expression levels of all 
genes were normalized to Actb for adipose tissue and Gapdh for muscle tissue after confirming 
that these mRNAs are unaffected by dexamethasone or HFD treatment.  Data were analyzed 
using the ∆∆Ct method after evaluation of several reference genes.   qPCR primer sequences are 
listed in Table 1.  Statistical tests were performed as described below based on tests of normality 
and homoscedasticity, then p-values were adjusted for multiple comparisons based on the 
number of genes tested for each tissue across this manuscript. 
 
Protein Extraction and Analysis 
Cells and tissues were lysed in RIPA buffer (50 mM Tris, pH 7.4, 0.25% sodium deoxycholate, 
1% NP40, 150 mM sodium chloride, 1 mM EDTA, 100 uM sodium orthovanadate, 5 mM 
sodium fluoride, 10 mM sodium pyrophosphate and 1x protease inhibitor), centrifuged at 
14,000rpm for 10 minutes at 4°C.  Lysates were heated with loading buffer at 85-95°C and 
proteins were separated by SDS-PAGE (Life Technologies) and transferred onto nitrocellulose 
membranes overnight at room temperature.  Membranes were blotted at room temperature using 
anti-adipose triglyceride lipase antibodies (ATGL; molecular weight 54; Cell Signaling 
Technologies; catalog #30A4, RRID:AB_2167953) and antibodies against hormone-sensitive 
lipase (HSL; molecular weight 81; Cell Signaling Technologies; catalog #4107, 
RRID:AB_2296900) and its PKA phosphorylation sites on serine 563 and 660 (Cell Signaling 
Technologies; catalog #4139, RRID:AB_2135495 and #4126, RRID:AB_490997, respectively).  
Antibody complexes were detected by anti-mouse and anti-rabbit fluorescent conjugated 
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antibodies (Invitrogen) and visualized using an Odyssey CLx image scanner.  Blots were 
quantified using Image Studio software version 5.2 (LiCOR) and normalized to Revert Total 
Protein Stain (LiCOR; catalog #926-11011). 
 
Histology 
Tissues were fixed in 10% phosphate-buffered formalin for 24 hours and then stored in 70% 
ethanol until further processing.  Tissues were dehydrated, embedded in paraffin and sent to the 
University of Michigan Comprehensive Cancer Center Tissue Core where they were processed 
and stained with hematoxylin and eosin (H&E) to assess cell morphology.  Slides were imaged 
using the 10x objective of an Olympus iX18 inverted microscope and cellSense software. 
 
Statistics 
For the human data, descriptive statistics including means and standard errors were determined 
for clinical measurements.  All statistical tests were performed using the R package (version 
3.0.2, (R Core Team 2013)).  Normality assumption was checked via Shapiro-Wilk test.  
Wilcoxon rank sum tests were used when data were not normally distributed.  Welch’s t-test was 
performed if the equal variance assumption was rejected by Levene's test (car package version 
2.0-19), otherwise a Student’s t-test was used.  Longitudinal measurements such as body weight, 
food intake, body composition and insulin tolerance tests were analyzed via mixed linear models 
and a c2 test between models with and without dexamethasone treatment as a covariate.  This 
used the lme4 package, version 1.1-7 (Bates et al. 2014).  To correct for multiple hypotheses, p-
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values were adjusted by the method of Benjamini and Hochberg (Benjamini and Hochberg 
1995).  Statistical significance in this study was defined as a p/q-value of less than 0.05.   For 
RNAseq, the DESeq2 algorithm excludes genes with very high variance to improve statistical 
power (Love, Huber, and Anders 2014).  The analysis we focused on in this manuscript was 
without adjustment for BMI or age and is presented in Supplementary Table 1 of (Hochberg, 
Harvey, et al. 2015).  All data are presented as mean +/- standard error of the mean. 
 
We used Gene Set Enrichment Analysis (GSEA v2.0.13 (Subramanian et al. 2005; Clark and 
Ma’ayan 2011)) to determine whether our rank-ordered gene list for the comparison of Cushing's 
disease versus control patients is enriched in genes from gene ontology, KEGG, transcription 
factor or microRNA target gene sets (MSigDB version 4.0).  The gene list was ranked based on 
t-statistics and the statistical significance of the enrichment score was determined by performing 
1000 phenotype permutations.  Other settings for GSEA were left to the software defaults.  
GSEA results are summarized in Table 3.   
 
For the mouse findings, all data are presented as mean +/- standard error of the mean.   For 
animal studies, two-way ANOVA analyses were performed to test for significance of diet and 
dexamethasone treatment, as well as their interaction.  Pairwise comparisons, normality and 
equal variance were tested using Shapiro-Wilk and Levene’s tests, respectively.   Pending those 
results, a Mann-Whitney, Welch’s or Student’s t-test were used.  P-values below p=0.05 were 
considered significant.   All statistical tests were performed using the R software package version 
3.30.  All code and raw data from this study are available through the Gene Expression Omnibus 
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(GSE66446) and at http://bridgeslab.github.io/CushingAcromegalyStudy (Hochberg, Tran, et al. 
2015). 
 
Results 
Patient Characteristics 
Clinical and metabolic measurements were obtained for five Cushing's disease patients and 11 
control subjects, who were admitted with non-secreting adenomas.  Patient characteristics are 
shown in Table 2.  Cushing’s disease patients were in general younger and had smaller tumors 
than the patients with non-secreting adenomas.   In the Cushing’s disease cohort there was a non-
significant elevation in body weight (p=0.47), body mass index (BMI) (p=0.27) and abdominal 
circumference (p=0.07, Figure 1A), consistent with Cushing’s disease patients having elevated 
fat mass and truncal obesity (Lamberts and Birkenhäger 1976). 
 
Table 1: Primer sequences used for qPCR analyses. 
Gene Forward 5’-3’ Sequence  Reverse 5’-3’ Sequence  
Acaca GCTAAACCAGCACTCCCGAT GTATCTGAGCTGACGGAGGC 
Aco1 AACACCAGCAATCCATCCGT GGTGACCACTCCACTTCCAG 
Acsl1 GCCTCACTGCCCTTTTCTGA GCAGAATTCATCTGTGCCATCC 
Acss2 CGTTCTGTGGAGGAGCCAC GGCATGCGGTTTTCCAGTAA 
Actb ATGTGGATCAGCAAGCAGGA AAGGGTGTAAAACGCAGCTCA 
Agpat2 CGTGTATGGCCTTCGCTTTG TCCATGAGACCCATCATGTCC 
Dgat2 AACACGCCCAAGAAAGGTGG GTAGTCTCGGAAGTAGCGCC 
Dhcr7 ATGGCTTCGAAATCCCAGCA GAACCAGTCCACTTCCCAGG 
Dhcr24 AGCTCCAGGACATCATCCCT TACAGCTTGCGTAGCGTCTC 
Fasn GGAGGTGGTGATAGCCGGTA
T 
TGGGTAATCCATAGAGCCCAG 
Gapdh CACTTGAAGGGTGGAGCCAA 
 
ACCCATCACAAACATGGGGG 
  
 
 
 31 
Gpam AGCAAGTCCTGCGCTATCAT 
 
 CTCGTGTGGGTGATTGTGAC 
 
Gpd1 GTGAGACGACCATCGGCTG TTGGGTGTCTGCATCAGGT 
Idh1 CTCAGAGCTCTCTTGGACCGA CATCTCCTTGCATCTCCACCA 
Ldhb AAAGGCTACACCAACTGGGC GCCGTACATTCCCTTCACCA 
Mdh1 GGAACCCCAGAGGGAGAGTT TGGGGAGGCCTTCAACAAAC 
Me1 GGACCCGCATCTCAACAAG TCGAAGTCAGAGTTCAGTCGT
T 
Psmd1 TGCCAATCATGGTGGTGACA ACACATCCTGACGTGCAGTT 
Psmd8 ACGAGTGGAACCGGAAGAAC CCGTGGTTGGCAGGAAATTG 
Rplp0 GAAACTGCTGCCTCACATCCG GCTGGCACAGTGACCTCACAC
G 
Rplp13a GCGGATGAATACCAACCCCT CCTGGCCTCTCTTGGTCTTG 
Scd1 CACTCGCCTACACCAACGG AACTGGAGATCTCTTGGAGC
A 
 
 
We detected a non-significant elevation in HOMA-IR score (2.6 Fold, p=0.67 by Wilcoxon test, 
Figure 1B), driven largely by increases in fasting insulin levels (p=0.30).  Three out of the five 
Cushing's disease patients had diabetes, while only 1 of the 11 controls had diabetes (p=0.03 via 
c2 test).  These data are consistent with disrupted glucose homeostasis often seen in patients with 
Cushing’s syndrome.  We observed significant elevations in both ALT and AST in serum from 
Cushing’s disease patients, indicative of liver disease (Figure 1C).  To evaluate lipolysis in 
explants from these patients we measured glycerol release from isolated subcutaneous adipose 
tissue and found a 3.1-fold elevation in glycerol release from these tissues (p=0.049 via Student’s 
t-test; Figure 1D).  These data support previous studies which implicate elevated lipolysis (Kršek 
et al. 2006) and higher rates of non-alcoholic fatty liver disease in Cushing’s disease patients 
(Rockall et al. 2003).   
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Table 2:  Clinical characteristics of Cushing’s disease and control patients.  Data represents 
mean +/- standard error.   
 
Cushing's disease 
(n=5) Controls (n=11) p-value 
Height (cm) 166 ± 4.3 169 ± 2.4 0.47 
Tumor size (cm) 0.95 ± 0.3 1.96 ± 0.14 0.01 
Age (years) 39.8 ± 4.5 63.4 ± 2.7 0.0003 
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Table 3: Summarized gene set enrichment analysis of pathways.  Selected pathway enriched 
in subcutaneous adipose tissue from Cushing’s disease patients via GSEA analysis.  NES is the 
net enrichment score, asterisk indicates q<0.25. For a complete list see Supplementary Tables 2-
3 of (Hochberg, Harvey, et al. 2015). 
 
Pathway Dataset NES 
M_PHASE_OF_MITOTIC_CELL_CYCLE Gene Ontology   2.60* 
KEGG_CITRATE_CYCLE_TCA_CYCLE KEGG   2.41* 
KEGG_BIOSYNTHESIS_OF_UNSATURATE
D_FATTY_ACIDS 
KEGG   2.41* 
REACTOME_TRIGLYCERIDE_BIOSYNTHE
SIS 
Reactome   2.24* 
PYRUVATE_METABOLISM Gene Ontology   2.24* 
KEGG_VALINE_LEUCONE_AND_ISOLEUC
INE_DEGRADATION 
KEGG   2.16* 
STEROID_BIOSYNTHETIC_PROCESS Gene Ontology   2.11* 
KEGG_STARCH_AND_SUCROSE_METABO
LISM 
KEGG   2.08* 
PROTEASOME_COMPLEX Gene Ontology   1.78* 
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KEGG_ALLOGRAFT_REJECTION KEGG -1.87* 
KEGG_BASAL_CELL_CARCINOMA KEGG -1.86* 
KEGG_RIBOSOME KEGG -2.33* 
 
Dexamethasone Treatment of Mice as a Model of Cushing’s Syndrome 
To validate the gene expression changes observed in human subjects, we treated C67BL/6J mice 
with dexamethasone, a synthetic glucocorticoid in their drinking water to mimic the systemic 
effects of cortisol 
overproduction.  
Dexamethasone-treated mice 
had an initial catabolic phase 
in which their body weight 
was rapidly reduced (Figure 
2A) and at the end of the 
study this resulted in a 
19.34% decrease in body 
weight (p<0.001), an effect 
that was primarily in due to a 
reduction in lean body mass, 
which will be discussed in 
Chapter 4. After 
 
Figure 1: Metabolic characteristics of Cushing’s disease patients.  A) 
Morphometric data from control (non-secreting adenoma) and Cushing’s disease 
subjects.  A.C indicates abdominal circumference.  B) HOMA-IR score, fasting 
insulin and fasting blood glucose from subjects.  C) Liver enzymes from subjects D) 
Glycerol release from isolated subcutaneous adipose tissue. Asterisks indicates 
p<0.05. 
 
 
 
Figure 1: Metabolic characteristics of Cushing’s disease patients.  A) Morphometric 
data from control (non-secreting adeoma) and Cushing’s disease subjects.  A.C 
indicates abdominal circumference.  B) HOMA-IR score, fasting insulin and fasting 
blood glucose from subjects.  C) Liver enzymes from subjects D) Glycerol release 
from isolated subcutaneous adipose tissue. Aste 
risks indicates p<0.05.  
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approximately five weeks, we observed significant elevations in total fat mass (40.38% increase; 
p=0.008) and percent adiposity (71.59% increase; p<0.001) in the dexamethasone treated mice 
(Figure 2B-D), as well as significantly elevated inguinal white adipose tissue (iWAT; p=0.041) 
following 12 weeks of treatment when normalized to total body weight (Figure 2D).  We did not 
detect a difference in food intake between the groups throughout the study that would account 
for the difference in fat mass (Figure 2E).  To evaluate insulin sensitivity, we performed insulin 
tolerance tests (ITT) on these mice after 12 weeks of dexamethasone treatment and found that 
while they had reduced fasting glucose at this stage, they were resistant to insulin-induced 
reductions in blood glucose (Figure 2F).  
 
 
 
Transcriptomic Analysis 
of Human Adipose Tissue 
from Cushing’s Patients 
To determine which genes and 
pathways are altered in 
adipose tissue in the human 
Cushing's disease subjects, we 
analyzed the transcriptome 
from subcutaneous adipose 
z
 
Figure 2: Dexamethasone treatment results in increased fat mass in mice and 
severe insulin resistance. Weekly body weight (A), fat mass (B), percent fat mass 
(C) inguinal (IWAT) and epididymal (EWAT) fat pad weights (D), average food 
consumption per mouse per day E) and ITT (F) from control dexamethasone 
treated mice.  ITT was administered following a 6 hour fast, insulin (1 mU/g). 
Asterisks indicate p<0.05.   
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tissue mRNA from the five Cushing's disease patients and 11 controls.  We identified 473 genes 
that had significantly different expression in Cushing's disease patients, of these 192 genes were 
expressed at a lower level and 281 at a higher level in the adipose tissue from the disease 
patients.  These transcripts form a signature identifying transcriptional differences in adipose 
tissue in response to long-term exposure to glucocorticoids (Figure 3A).    
 
To identify conserved 
pathways underlying 
these changes, a gene 
set enrichment analysis 
was performed on these 
data.  As summarized in 
Table 3, we detected 
enrichment of genes in 
several categories 
involved in metabolism, 
including higher 
expression of gene sets 
involved in lipid 
biosynthesis, glucose 
metabolism, activation 
of amino acid 
degradation, protein degradation, and reductions in protein synthesis.  We also observed reduced 
 
Figure 3: Differentially expressed transcripts in subcutaneous adipose tissue from 
Cushing’s disease subjects.  A) Heatmap of genes with significant differential 
expression.  The bar on the top indicates control subjects (non-secreting adenoma; black) 
and Cushing’s subjects (red). B) Genes involved in cortisol signaling.  C) Leptin and 
Adiponectin mRNA levels. Asterisks indicate q<0.05. 
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expression of transcripts involved in immune function that will be discussed in subsequent 
sections. 
 
We next evaluated the transcript levels of the glucocorticoid receptor (NR3C1) and the 
mineralocorticoid receptor (NR3C2) genes and observed no significant downregulation of these 
receptors at the mRNA level in Cushing’s patients (Figure 3B).  Another potential mechanism 
for negative feedback of glucocorticoid signaling is through the enzymatic activities of 11ß-
HSD1/2 which control the local concentrations of cortisol in adipose tissues.  We observed a 
non-significant reduction in HSD11B1 mRNA levels (24% reduced, padj=0.49), potentially 
desensitizing adipose tissue to cortisol by reducing the conversion of cortisone to cortisol.  
Induction of leptin by glucocorticoids has been previously reported in human adipocytes 
(Halleux et al. 1998) and in human adipose tissue in vivo (Papaspyrou-Rao et al. 1997).  We 
observed 1.8-fold higher level of Leptin (LEP) expression (padj=0.014) and non-significantly 
higher resistin (RETN) expression but no significant changes in adiponectin mRNA levels 
(ADIPOQ, padj=0.94; Figure 3C).    
  
Lipogenesis Genes are Upregulated in Response to Elevated Glucocorticoids 
Increased subcutaneous fat mass is a hallmark of Cushing’s syndrome and could potentially be 
mediated through activation of adipogenesis or lipogenesis.  Our transcriptomic data support the 
hypothesis that lipogenesis is activated in these tissues via transcriptional activation of genes 
involved in fatty acid synthesis and triglyceride synthesis.  Key fatty acid synthesis transcripts 
were significantly elevated including ACACA (padj=0.035), FASN (padj=0.003)=, ACSL1 
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(padj=0.025), and ELOVL5 (padj=0.016; Figure 4A).  Desaturation of fatty acids is an essential 
aspect of de novo fatty acid synthesis, we observed elevations in all fatty acid desaturases SCD 
(padj<0.001), FADS1 (not significant, NS), FADS2 (NS) and HSD17B12 (NS; Figure 4B) as 
well as triglyceride synthesis genes GPAM (padj=0.004), DGAT1 (NS), DGAT2 (padj=0.01), 
 
Figure 4: Elevated glucocorticoids result in elevated fatty acid and triglyceride synthesis genes.  A) Fatty acid synthesis 
genes in Cushing’s disease and control patients. B) Fatty acid desaturases in Cushing’s disease patients. C) Triglyceride 
synthesis genes. D) Lipolysis genes. E) Steroid biogenesis genes.  F)  Evaluation of lipogenic genes in mouse subcutaneous 
adipose tissue.  Asterisks for human transcripts indicate padj<0.05; mice p<0.05. 
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AGPAT2/3 (NS), and GPD1 (NS) in subcutaneous adipose tissue from Cushing’s disease 
patients (Figure 4C).    
 
Despite increased lipid deposition and elevations of lipogenesis genes in Cushing’s disease 
patients' adipose tissue, there have been several studies linking elevated glucocorticoids to 
increased lipolysis, potentially as a way to stimulate hepatic gluconeogenesis.  In our patients, 
 
Figure 5:  Glycolysis and glucose oxidation genes are upregulated with elevated glucocorticoids.  Schematic of A) 
glycolysis and B) the TCA cycle, colored by gene expression changes in subcutaneous adipose tissue from Cushing’s 
disease subjects.  C) qPCR analysis of selected glucose oxidation genes from mouse subcutaneous adipose tissue after 12 
weeks of dexamethasone treatment.   
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we observed an increase in glycerol release in ex vivo explants of subcutaneous adipose tissue 
(Figure 1D), indicating elevated lipolysis.  Among genes that may liberate fatty acids from 
triglycerides, Lipoprotein Lipase (LPL) was induced 1.45 fold (padj=0.055) in the Cushing’s 
disease subjects, but neither Hormone Sensitive Lipase (LIPE) nor Adipose Triglyceride Lipase 
(PNPLA2) were significantly changed at the transcriptional level (Figure 4D). Additionally, we 
detected an elevation of Perilipin 4 (PLIN4) which is one of the proteins that coat intracellular 
lipid storage droplets and is important for lipolysis (induced 1.45-fold, padj=0.056, see 
Supplementary Table 1 of (Hochberg, Harvey, et al. 2015)).   
 
 
 Figure 6: Increased glucocorticoids are associated with increased protein degradation and decreased strength.  
Proteasomal transcript expression changes in subcutaneous adipose tissue from Cushing’s disease and control subjects 
(A) and mouse iWAT following 12 weeks of dexamethasone treatment (B). Protein catabolism transcript expression 
changes (C) and heatmap of differentially expressed ribosomal transcripts (D) in subcutaneous adipose tissue from 
Cushing’s disease and control subjects. 
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 Several genes that regulate steroid biogenesis were elevated in adipose tissue from Cushing’s 
disease patients as described in Figure 4E.   These include several cytochrome P450 family 
members, steroid reductases (SRD5A1, SRD5A3; NS), Aldo-keto reductase family 1 member C1 
(AKR1C1; padj=0.012), 7- and 24-dehydrocholesterol reductases (DHCR7, padj=0.026; 
DHCR24, padj<0.001) and HMG-CoA synthase (HMGCS1; padj=0.002).   
 
To examine whether lipogenesis genes are activated in the dexamethasone treated mice, we 
tested several lipogenic genes in subcutaneous adipose tissue, and observed general elevations in 
the lipid synthesis pathway Fasn (NS), Gpam  (padj=0.047), Gpd1(padj=0.047), Acss2 (NS), 
Acs1(NS), Dgat (NS), Agpat2 (NS), Dhcr7 (NS), Dhcr24 (padj=0.047) and Acaca1 (NS, 
padj=0.07; Figure 4F).  In contrast to the human samples, did not observe an elevation in the 
mouse isoform of SCD, but saw instead a non-significant reduction in Scd1 mRNA (padj=0.260). 
 
Genes Controlling Glucose Oxidation Are Elevated in Cushing's Disease Patients 
Several glucose metabolism genes, and specifically glycolysis and TCA cycle genes were 
expressed at higher levels in Cushing's disease patients (Figure 5).   Strongly induced genes 
included HK3 (NS), FBP1 (NS), ALDOC (padj<0.001), ENO1 (padj=0.004), IDH1 (padj=0.036), 
ME1 (padj<0.001) and DLAT (NS).  Consistent with human adipose tissue findings, elevations in 
Idh1 and Me1 were also noted in mouse adipose tissue, along with other transcripts involved in 
glucose oxidation such as Aco1, Ldhb and Mdh1; however, these did not reach statistical 
significance (padj>0.05; Figure 5C). 
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The major glycogen synthesis transcripts were also induced, including GYS2 (padj=0.004), 
UGP2 (padj=0.01) and GBE1 (padj=0.027).  This agrees with biochemical studies which 
implicate glucocorticoid treatment in elevated hepatic and adipose tissue glycogenesis (Engel 
and Scott 1951; Baqué et al. 1996; Segal and Gonzalez Lopez 1963).  The relevance of this 
effect in adipose tissue has not yet been explored.   
 
Genes That Regulate Protein Catabolism are Upregulated in Adipose Tissue 
from Glucocorticoid Exposed Subjects 
We found two major pathways of protein 
homeostasis altered in response to 
glucocorticoids.   
In adipose tissue from Cushing’s disease 
patients, we observed inductions of both the 
proteasomal pathways (via KEGG, net 
enrichment score 1.76, padj=0.01; Figure 6A), 
with Psmd1 and Psmd8 also observed to be 
elevated in mouse adipose tissue following 
dexamethasone treatment (Figure 6B), and 
genes involved in amino acid catabolism 
(Figure 6C) and a general downregulation of 
ribosomal genes (Figure 6D).  Among the 
amino acid catabolism genes, AOX1 (96% increase, padj=0.03), OXCT1 (40% increase, 
 
 Figure 7: Expression of insulin signaling 
transcripts, ceramides and inflammatory 
transcripts in control vs. Cushing’s disease subjects. 
A) Insulin signaling transcript expression levels. B) 
MHC complex transcript expression levels. 
